Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-17T18:03:49.898Z Has data issue: false hasContentIssue false
  • English
  • Français

The effects of systemic steroid therapy on macrophage migration inhibitory factor concentrations in patients with nasal polyps

Published online by Cambridge University Press:  01 October 2018

A Ekinci
A Ekinci*
Affiliation:
Otorhinolaryngology Department, Faculty of Medicine, Hitit University, Çorum, Turkey
*
Author for correspondence: Dr Adnan Ekinci, Üçtutlar Mh, Ahçılar 16, Sokak, Ada Aparmant B Blok no: 15, 19000, Çorum, Turkey E-mail: draekinci@hotmail.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives

This study aimed to compare serum macrophage migration inhibitory factor concentrations before and after oral steroid therapy in nasal polyps patients, and determine whether there is a difference between pre-treatment macrophage migration inhibitory factor concentrations and healthy individuals.

Methods

The study included 24 patients with nasal polyps and 25 healthy individuals. The patient group received 1 mg/kg oral steroid.

Results

The mean macrophage migration inhibitory factor concentration before oral steroid therapy was 3889.79 pg/ml in the patient group and 2334.52 pg/ml in the control group. Macrophage migration inhibitory factor concentrations were statistically significantly higher in the pre-oral steroid therapy patient group than in the control group (p = 0.017). The mean pre- and post-oral steroid therapy serum macrophage migration inhibitory factor concentrations were 3889.79 pg/ml and 2451.25 pg/ml, respectively. The reduction in macrophage migration inhibitory factor concentrations was statistically significant (p = 0.010).

Conclusion

These findings suggest that concentrations of macrophage migration inhibitory factor may play a role in the pathogenesis of nasal polyps.

Keywords

Nasal PolypsMacrophage Migration-Inhibitory FactorsSteroids
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 132 , Issue 10 , October 2018 , pp. 891 - 895
Copyright
Copyright © JLO (1984) Limited, 2018 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Dr A Ekinci takes responsibility for the integrity of the content of the paper

References

1Koc, C. Nasal Polyps, Otolaryngology, Head and Neck Surgery [in Turkish]. Ankara: Güneş Kitabevi, 2004;609–24Google Scholar
2Keles, B, Cora, T, Acar, H, Arbag, H, Inan, Z, Ozturk, K et al. Evaluation of HLA-A, -B, -Cw, and-DRB1 alleles frequency in Turkish patients with nasal polyposis. Otolaryngol Head Neck Surg 2008;139:580–5Google Scholar
3Settipane, GA, Lund, VJ, Tos, M. Nasal Polyps: Epidemiology, Pathogenesis and Treatment. Providence, RI: Oceanside Publications, 1997Google Scholar
4Calandra, T, Berhagen, J, Metz, CN, Spiegel, LA, Bacher, M, Donnelly, T et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995;377:68–71Google Scholar
5Calandra, T, Roger, T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003;3:791–800Google Scholar
6Santos, LL, Morand, EF. The role of macrophage migration inhibitory factor in the inflammatory immune response and rheumatoid arthritis. Wien Med Wochenschr 2006;156:11–18Google Scholar
7Calandra, T, Bernhagen, J, Mitchell, RA, Bucala, R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 1994;179:1895–902Google Scholar
8Donn, R, Ray, D. Macrophage migration inhibitory factor: molecular, cellular and genetic aspects of a key neuroendocrine molecule. J Endocrinol 2004;182:1–9Google Scholar
9Hopkins, C, Browne, JP, Slack, R, Lund, V, Brown, P. The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict? Otolaryngol Head Neck Surg 2007;137:555–61Google Scholar
10Lue, H, Kleemann, R, Calandra, T, Roger, T, Bernhagen, J. Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. Microbes Infect 2002;4:449–60Google Scholar
11Kitaichi, N, Shimizu, T, Honda, A, Abe, R, Ohgami, K, Shiratori, K et al. Increase in macrophage migration inhibitory factor levels in lacrimal fluid of patients with severe atopic dermatitis. Graefes Arch Clin Exp Ophthalmol 2006;244:825–8Google Scholar
12Li, C, Ma, H, Ba, Y. The expression and role of MIF, NF-κB and IL-1β in nasal polyps [in Chinese]. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2016;30:220–5Google Scholar
13Delbrouck, C, Gabius, HJ, Vandenhoven, G, Kiss, R, Hassid, S. Budesonide-dependent modulation of expression of macrophage migration inhibitory factor in a polyposis model: evidence for differential regulation in surface and glandular epithelia. Ann Otol Rhinol Laryngol 2004;113:544–51Google Scholar
14Mitchell, R, Bacher, M, Bernhagen, J, Pushkarskaya, T, Seldin, M, Bucala, R. Cloning and characterization of the gene for mouse macrophage migration inhibitory factor (MIF). J Immunol 1995;154:3863–70Google Scholar
15Stathas, T, Athanassiou, S, Drakouli, S, Giannopoulou, E, Mastronikolis, NS, Naxakis, S et al. MIF attenuates the suppressive effect of dexamethasone on IL-6 production by nasal polyp. Eur Rev Med Pharmacol Sci 2013;17:1455–66Google Scholar
16Rossi, AG, Haslett, C, Hirani, N, Greening, AP, Rahman, I, Metz, C et al. Human circulating eosinophils secrete macrophage migration inhibitory factor (MIF). Potential role in asthma. J Clin Invest 1998;101:2869–74Google Scholar
17Nakamaru, Y, Takagi, D, Oridate, N, Furuta, Y, Nishihira, J, Fukuda, S. Macrophage migration inhibitory factor in allergic rhinitis: its identification in eosinophils at the site of inflammation. Ann Otol Rhinol Laryngol 2004;113:205–9Google Scholar
18Kozacı, LD, Chikanza, IC, Eyigör, H, Döğer, F, Kavak, T, Evci, D et al. Effects of topical mometasone furoate therapy on local and systemic macrophage migration inhibitory factor levels in allergic rhinitis patients [in Turkish]. Meandros Med Dent J 2005;6:23–7Google Scholar
19Cvetkovic, I, Al-Abed, Y, Miljkovic, D, Maksimovic-Ivanic, D, Roth, J, Bacher, M et al. Critical role of macrophage migration inhibitory factor activity in experimental autoimmune diabetes. Endocrinology 2005;146:2942–51Google Scholar
20Yang, N, Nikolic-Paterson, DJ, Ng, YY, Mu, V, Metz, C, Bacher, M et al. Reversal of established rat crescentic glomerulonephritis by blockade of macrophage migration inhibitory factor (MIF): potential role of MIF in regulating glucocorticoid production. Mol Med 1998;4:413–24Google Scholar
21Denkinger, CM, Denkinger, M, Kort, JJ, Metz, C, Forsthuber, TG. In vivo blockade of macrophage migration inhibitory factor ameliorates acute experimental autoimmune encephalomyelitis by impairing the homing of encephalitogenic T cells to the central nervous system. J Immunol 2003;170:1274–82Google Scholar
22Matsui, Y, Okamoto, H, Jia, N, Akino, M, Uede, T, Kitabatake, A et al. Blockade of macrophage migration inhibitory factor ameliorates experimental autoimmune myocarditis. J Mol Cell Cardiol 2004;37:557–66Google Scholar
23Al-Abed, Y, Dabideen, D, Aljabari, B, Valster, A, Messmer, D, Ochani, M et al. ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J Biol Chem 2005;280:36541–4Google Scholar